High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group

• Published in: Oncology letters Vol. 18; no. 6; pp. 5811 - 5820
• Main Authors: Hus, Iwona, Manko, Joanna, Jawniak, Dariusz, Jurczyszyn, Artur, Charlinski, Grzegorz, Poniewierska-Jasak, Katarzyna, Usnarska-Zubkiewicz, Lidia, Sawicki, Mateusz, Druzd-Sitek, Agnieszka, Swiderska, Alina, Kopinska, Anna, Grzasko, Norbert, Razny, Malgorzata, Wedlowska, Aleksandra, Perzynski, Aleksander, Galazka, Aleksandra, Dytfeld, Dominik, Kubicki, Tadeusz, Rodzaj, Marek, Waszczuk-Gajda, Anna, Drozd-Sokolowska, Joanna, Poglodek, Bartlomiej, Pasternak, Anna, Dlugosz-Danecka, Monika, Szymczyk, Agnieszka, Dmoszynska, Anna
• Format: Journal Article
• Language: English
• Published: Athens Spandidos Publications 01.12.2019; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Bortezomib; Cytogenetics; Dexamethasone; Drug dosages; Glucocorticoids; Multiple myeloma; Oncology; Patients; Proteins; Stem cell transplantation; Stem cells; Thrombosis; Transplants & implants; Poland
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2019.10929

The present retrospective analysis evaluated the efficacy and safety of the VTD (bortezomib, thalidomide, dexamethasone) regimen in 205 newly-diagnosed patients with multiple myeloma (MM) eligible for high dose therapy and autologous stem cell transplantation (HDT/ASCT) in routine clinical practice. With a median of 6 cycles (range, 1-8), at least partial response was achieved in 94.6% and at least very good partial response (VGPR) was achieved in 67.8% of patients. Peripheral neuropathy (PN) grade 2-4 was observed in 28.7% of patients. In 72% of patients undergoing stem cell mobilization one apheresis allowed the number of stem cells sufficient for transplantation to be obtained. Following HDT/ASCT the sCR rate increased from 4.9 to 14.4% and CR from 27.8 to 35.6%. The results demonstrated that VTD as an induction regimen was highly efficient in transplant eligible patients with MM with increased at least VGPR rate following prolonged treatment ([greater than or equal to]6 cycles). Therapy exhibited no negative impact on stem cell collection, neutrophils and platelets engraftment following ASCT. Therapy was generally well tolerated and PN was the most common reason of dose reduction or treatment discontinuation.